Product Description
AI Product Description
*The following content is generated by AI and is for reference only.
Vildagliptin, chemically known as (3S)-3-amino-1-(3-fluorophenyl)-4-(2,4,5-trifluorophenyl)-butan-2-one, is a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor primarily utilized in the management of type 2 diabetes mellitus. Its molecular formula is C16H18F4N2O, with a corresponding CAS Registry Number of 205161-65-9. This pharmaceutical agent functions by inhibiting the enzyme DPP-4, which is responsible for the rapid degradation of incretin hormones, specifically glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By preventing this enzymatic breakdown, Vildagliptin effectively prolongs the half-life of these endogenous incretins, thereby enhancing glucose-dependent insulin secretion from pancreatic beta cells while simultaneously suppressing inappropriate glucagon release from alpha cells.
Clinically, Vildagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes. It is often prescribed as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or thiazolidinediones when single therapy fails to achieve target blood glucose levels. A distinct advantage of Vildagliptin lies in its mechanism of action; unlike sulfonylureas or insulin secretagogues, it does not stimulate insulin release independently of blood glucose concentrations. Consequently, the risk of hypoglycemia when used alone is minimal, making it a favorable option for patients concerned about low blood sugar events. Furthermore, it is generally weight-neutral, avoiding the weight gain often associated with other diabetes medications. The drug is typically administered orally in tablet form, usually twice daily, due to its pharmacokinetic profile. Extensive clinical trials have demonstrated its efficacy in lowering hemoglobin A1c levels without significant adverse effects on body weight or cardiovascular safety concerns in the short to medium term. As a member of the gliptin class, Vildagliptin represents a crucial advancement in oral antidiabetic therapy, offering a targeted approach to restoring physiological glucose regulation in diabetic populations worldwide.